RecruitingNCT01503190
The Immune System's Response to Young Women's Breast Cancer
A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction
Sponsor
University of Colorado, Denver
Enrollment
800 participants
Start Date
Jul 21, 2009
Study Type
OBSERVATIONAL
Conditions
Summary
This study plans to learn more about the immune system's response to breast cancer in young women.
Eligibility
Sex: FEMALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is investigating how the immune system responds to breast cancer in younger women, by analyzing tumor tissue and blood samples to look for patterns that could predict treatment outcomes and guide better therapies.
**You may be eligible if...**
- You are a woman over 18 years old
- You have been diagnosed with breast cancer (confirmed by lab testing)
- Tumor tissue samples are available or will be available from your biopsy or surgery
- You are willing to have fresh tissue collected during your procedure
**You may NOT be eligible if...**
- You are unwilling to have tissue samples collected
- You are unable to provide informed consent
- Tumor tissue is not available and cannot be collected
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01503190
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations